Quarterly results - GSK
WEBFind the latest financial performance announcement and historical materials for GSK's quarterly results. Download slides, transcripts, reports and infographics for Q1 2024 and Q2 2024, as well as FY 2023 and Q3 2023.
Investors | GSK
WEBFind the latest Annual Report 2023 and Q2 2024 results of GSK, a global healthcare company. Learn about GSK's growth, dividend, share price, ESG and investor events.
WEBGSK delivered a strong first half 2024 performance with excellent business momentum, including increased sales growth of Specialty Medicines, particularly reflecting successful new launches in Oncology and for long-acting HIV
GSK sees strong growth as Haleon split and vaccine drive pays off
WEBJan 31, 2024 · GSK beat market estimates for fourth-quarter results on Wednesday, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the...
GSK beats expectations, shingles vaccine bolsters outlook
WEBFeb 1 (Reuters) - GSK (GSK.L) on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix and unveiled an upbeat forecast for 2023....
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, …
WEBJun 23, 2021 · GSK reports strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER, and improved operating margin and Adjusted EPS. The company also provides guidance for 2022, outlooks for medium term growth, and updates on COVID-19 solutions and pipeline progress.
Cost discipline supports delivery of Adjusted EPS of 113.2p - GSK
WEBFeb 9, 2022 · Highlights. Full results announcement (PDF) Download the FY 2021 results announcement. FY 2021 results announcement (PDF, 1.1MB) Strong commercial execution drives growth across Pharmaceuticals, Vaccines and Consumer Healthcare (excluding brands divested/under review)
WEBGSK delivers strong Q3 sales of £9.1 billion +5% AER, +10% CER Total EPS 23.3p -7% AER, +3% CER; Adjusted EPS 36.6p +3% AER, +10% CER 2021 full year EPS guidance improved. Highlights .
GSK's fourth-quarter results beat market estimate, sees 2024 …
WEBJan 31, 2024 · GSK beat market estimates for fourth-quarter profit and sales on Wednesday, underpinned by a strong launch of its respiratory syncytial virus (RSV) vaccine Arexvy and steady demand for its...
GSK stays strong as healthy sales beat expectations | Reuters
WEBApr 26, 2023 · GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well as HIV and respiratory...